Title: Autoantibodies and Disability in Long-Standing Rheumatoid Arthritis
Authors: Sami Abdulahakim, Abdualziz Abdulhamied, Hamdy Samy Naser, Abdelfattah Kasem, Nassar, Ashraf Abd-Elmonem Abotaleb, Mohamed Rashed Abdelhamed, Shereen Rashad, Kaddafy
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.171
Abstract
Objective: This study analyzed RF and MCV relationship with HAQ score to predict disability in rheumatoid arthritis patient on DMARD therapy.
Method: This study was conducted among 92 female patients with rheumatoid arthritis selected from different rheumatology OPD clinic; RF, MCV, ESR, CBC, STDWL, SDAI, HAQ Di self-reports, VAS scale, deformity and disease comorbidity were recorded in this study.
Results: the results of this study showed, age 38.09±3.30 years, disease duration 6.45±1.17, rheumatoid factor 65.57±67.27, SDAI was 48.51± 25.02, STDL 26.15±13.30. HAQ-Di was 2.45±.1.17, anti-MCV 157.89±255.92, and VAS 5.92±2.65. There is a significant relation with MCV and positive correlation with extra-articular manifestation, Deformity and STDWLP<0.05. But, RF has a significant relation with STDWL, SDAI P<0.05. Otherwise, no significant relation was seen P>0.05. Functional disability HAQ, VAS, ACR CLASS) in the study group showed a significant relation with both RF and MCV; MCV more significantly than RF P<0.05 with a significant positive correlation between HAQ, VAS with MCV P<0.05 but, not with RF P>0.05.
Conclusion: HAQ score is the simplest possible tool used to assess RA disease activity and highest was recorded was after 5th years duration of the disease activity in this study, but it should be recorded regularly during follow-up of the patient with RA to predict early future disability.
Keyword: disability, RA, HAQ-di.
References
1. Richard D. &Brasington, Jr. Clinical features of rheumatoid arthritis, RHEU-MATOLOGY, text book 5th edition, MOSBY ELSEVIER, 2006, 829- 838.
2. Dörner T, Egerer K, Feist E, Burmester GR: Rheumatoid factor revisited. CurrOpinRheumatol 2004; 16: 246-53.
3. Taylor P, Gartemann J, Hsieh J,et al. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid. arthritis. Autoimmune Dis 2011;815-538.
4. Vallbracht I, Rieber J, OppermannM,et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.Ann Rheum Dis 2004;63:1079–84.
5. Marc C Hochberg, Rowland W Chang, Isaac Dwosh, Theodore Pincus, Wolfe F, et al., The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992: 35(5): 498–502.
6. Taylor1., K. Colvine2, K. Gregory3, J. Collis2, F.M. McQueen3, N.Dalbeth3The Health Assessment Questionnaire Disa-bility Index is a valid measure of physical function. Clinical and Experimental Rheumatology 2008; 26: 620-626.
7. Hazes J.M.W. Determinants of physical function in rheumatoid arthritis: association with the disease process Rheumatology2003;42.
8. Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38:228–34.
9. Chopra A, Saluja M, Patil J, Tandale HS. Pain and Disability, Perceptions and Beliefs of a Rural Indian Population: A WHO ILAR COPCORD Study.J Rheumatol 2002;29:614-21
10. Susan T. Reisine, Kathleen E. Grady, Carol Goodenow, And Judith Fifield: Work Disability Among Women With Rheumatoid Arthritis Arthritis And Rheumatism, Vol. 32, No. 5, 1989
11. Senra H, Rogers H, Leibach G, et al. Health-related quality of life and depression in a sample of Latin American adults with rheumatoid arthritis. J Rheum Dis. 2014;7:1–10
12. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924–7.
13. Ursum J, Bos WH, van Dillen N, et al. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12:R8.
14. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.
15. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992. Arthritis Care Res. 1992; 5(3):119–1129.
16. Thorsen H, Hansen TM, Mc Kenna SP, Sørensen SF, Whalley D: Adaptation into Danish of the stanford health assessment questionnaire (HAQ) and the rheumatoid arthritis quality of life scale (RAQoL) Scand J Rheumatol. 2001; 30(2):103–109.
17. Kastbom A, Strandberg G, Lindroos A, et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085–9. 18